Full List Of Stories
Broker tips: Prudential, MJ Gleeson
Analysts at JP Morgan raised their target price from insurance firm Prudential from £13. 80 per share to £14. 50 on Friday to reflect foreign exchange movements and a roll-forward of its valuation.
US open: Stocks extend losses at the open
Wall Street stocks were firmly in the red early on Friday amid concerns that the central bank's aggressive monetary policy may send the US economy into a recession.
JP Morgan raises target price on Prudential
Analysts at JP Morgan raised their target price from insurance firm Prudential from £13. 80 per share to £14. 50 on Friday to reflect foreign exchange movements and a roll-forward of its valuation.
US pre-open: Stock futures lower amid ongoing recession fears
Wall Street futures were firmly in the red ahead of the bell on Friday amid concerns that the central bank's aggressive monetary policy may send the US economy into a recession.
Berenberg raises target price on MJ Gleeson
Analysts at Berenberg raised their target price on construction firm MJ Gleeson from 680. 0p to 710. 0p on Friday, stating the group was "well positioned" for the new trading year following its 2022 full-year results.
Eurozone manufacturing PMI falls in September
S&P Global's Eurozone manufacturing purchasing managers' index fell to 48. 5 in September from 49. 6 a month earlier, according to preliminary estimates.
Amigo Holdings CEO stands down
Credit provider Amigo Holdings revealed on Friday that chief executive Gary Jennison will stand down from the role and be released by chief financial officer Danny Malone.
Smiths Group FY pre-tax profits surge
Engineering company Smiths Group said on Friday that full-year organic revenues and pre-tax profits had grown ahead of expectations amid "high demand" across the majority of its end markets.
Smiths FY pre-tax profits surge, AstraZeneca's Ultomiris receives EU green light
London pre-open The FTSE 100 was being called to open 28. 2 points higher ahead of the bell on Friday after closing 1. 08% lower in the previous session at 7,159. 52.
AstraZeneca's gMG treatment receives EU approval
Drugmaker AstraZeneca said on Friday that Ultomiris, its long-acting C5 inhibitor, had received EU approval to be used in the treatment of adult patients with generalised myasthenia gravis, a rare autoimmune neuromuscular disease.